Talk:Lincomycin

Chemicals Mid‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Lincomycin.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

When discovered and when approved for clinical use

When was it discovered and when approved for clinical use ? - Rod57 (talk) 12:35, 13 March 2013 (UTC)[reply]

Comparison to macrolides

Under the 'Uses' heading the article states "Although similar in structure, antibacterial spectrum, and mechanism of action to macrolides...". Its activity and mechanism may be similar but its structure is very different from the macrolides — Preceding unsigned comment added by 207.237.221.18 (talk) 15:18, 9 November 2020 (UTC)[reply]

Agree; I've changed it for you.--Quisqualis (talk) 21:57, 9 November 2020 (UTC)[reply]